The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The inhibitory effects of dopamine on adenohypophysial cells are mediated via dopamine subtype 2 receptor (D2R). Dopamine agonists inhibit hormone release and induce tumor shrinkage in most prolactin-secreting adenomas, whereas in other adenoma types such effects are sporadic. We investigated D2R gene expression by in situ hybridization (ISH) and immunocytochemistry in different types of pituitary...
A European multicentre, open-label 12-month study with Sandostatin® LAR® administered intramuscularly at 4-week intervals was initiated in 151 acromegalics responsive to octreotide. All patients received 3 injections of the 20 mg dose, following which the dose was adjusted to 10 mg in patients with mean 4-hour GH serum concentrations below 1 µg/L (N: 29) and to 30 mg in patients with concentrations...
Double-blind, single-dose studies of 120 acromegalic patients given 10, 20, and 30 mg Sandostatin ( R) LAR ( R) (Sandoz Pharma Ltd, Basel, Switzerland) established the drug's pharmacokinetic profile. Patients then entered open-labeled extension phases, with Sandostatin ( R) LAR ( R) intramuscular (IM) injections every 4 weeks. These produced broadly constant octreotide...
Sandostatin LAR(R) was developed by incorporating octreotide in microspheres of the biodegradable polymer poly(dl-lactide-coglycolide glucose). One hundred acromegalics, 85 of whom were known to be ''responders'' to octreotide (subcutaneous [SC] Sandostatin(R) 0.1 to 0.2 mg three times daily), as measured by mean 12-hour growth hormone (GH) serum concentrations below 5 μg/L, were switched after a...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.